NYSE:BAX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	16,304	1,092	2,161	2,649	7
12/31/2025	15,749	878	2,117	2,508	13
12/31/2024	15,226	368	1,351	1,757	15
6/30/2024	14,997	-157	518	1,174	N/A
3/31/2024	14,892	-38	707	1,410	N/A
12/31/2023	14,813	-76	1,034	1,726	N/A
9/30/2023	15,280	225	891	1,634	N/A
6/30/2023	14,574	-3,050	888	1,559	N/A
3/31/2023	14,461	-2,673	837	1,482	N/A
12/31/2022	14,506	-2,666	591	1,211	N/A
9/30/2022	14,275	-2,568	792	1,465	N/A
6/30/2022	13,892	876	1,159	1,850	N/A
3/31/2022	13,396	992	1,341	2,053	N/A
12/31/2021	12,146	1,022	1,531	2,222	N/A
9/30/2021	12,451	1,214	1,496	2,241	N/A
6/30/2021	12,197	1,120	1,354	2,076	N/A
3/31/2021	11,817	1,068	1,265	1,973	N/A
12/31/2020	11,673	1,102	1,159	1,868	N/A
9/30/2020	11,531	911	1,236	1,985	N/A
6/30/2020	11,410	924	1,416	2,176	N/A
3/31/2020	11,526	991	1,487	2,248	N/A
12/31/2019	11,362	1,001	1,408	2,104	N/A
9/30/2019	11,156	1,335	1,201	1,984	N/A
6/30/2019	11,066	1,484	981	1,739	N/A
3/31/2019	11,060	1,505	929	1,698	N/A
12/31/2018	11,099	1,552	1,286	2,017	N/A
9/30/2018	11,063	1,065	1,020	1,699	N/A
6/30/2018	11,009	795	1,180	1,848	N/A
3/31/2018	10,763	840	N/A	2,095	N/A
12/31/2017	10,584	609	N/A	1,714	N/A
9/30/2017	10,432	1,025	N/A	2,036	N/A
6/30/2017	10,283	904	N/A	1,963	N/A
3/31/2017	10,263	1,852	N/A	2,176	N/A
12/31/2016	10,163	4,966	N/A	1,654	N/A
9/30/2016	10,121	4,909	N/A	1,665	N/A
6/30/2016	10,050	4,784	N/A	1,388	N/A
3/31/2016	9,940	3,646	N/A	1,342	N/A
12/31/2015	9,968	393	N/A	1,771	N/A
9/30/2015	10,154	337	N/A	2,190	N/A
6/30/2015	10,376	510	N/A	2,849	N/A
3/31/2015	9,274	84	N/A	2,752	N/A
12/31/2014	10,719	457	N/A	3,215	N/A
9/30/2014	12,252	739	N/A	3,155	N/A
6/30/2014	13,253	1,092	N/A	3,207	N/A
3/31/2014	15,367	1,967	N/A	3,371	N/A
12/31/2013	9,413	315	N/A	3,198	N/A
9/30/2013	14,398	2,097	N/A	3,060	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BAXは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.4% ) よりも高い成長率であると考えられます。

収益対市場: BAX今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: BAX今後 3 年以内に収益を上げることが予想されます。

収益対市場: BAXの収益 ( 3.2% ) US市場 ( 8.8% ) よりも低い成長が予測されています。

高い収益成長: BAXの収益 ( 3.2% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BAXの自己資本利益率は、3年後には低くなると予測されています ( 17.5 %)。

Baxter International 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Baxter International Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2024

Baxter International Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024

Baxter International Inc. Provides Sales Guidance for the First Quarter and Full Year 2024

Consensus EPS estimates increase by 109%

Price target decreased by 7.5% to US$45.07

Baxter International Inc. Provides Earnings Guidance for the Fourth Quarter and Year 2023

Recent updates

-Baxter International Inc. Appoints Jeffrey A. Craig to Its Board

Is Baxter International Inc. (NYSE:BAX) Trading At A 49% Discount?

Upcoming dividend of US$0.29 per share

The Carlyle Group Inc. (NasdaqGS:CG) and Atmas Health entered into an Equity Purchase Agreement to acquire Vantive Health LLC from Baxter International Inc. (NYSE:BAX) for $3.8 billion.

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Baxter- Reiterating Our Buy Rating After A Promising Q2

Baxter International (NYSE:BAX) Will Pay A Dividend Of $0.29

Baxter International Inc. Provides Earnings Guidance for the Third Quarter and Full Year 2024

Baxter International Inc. Announces Launch of the Helion Integrated Surgical System in Thailand

Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29

First quarter dividend of US$0.29 announced

Baxter International Inc. Declares Quarterly Dividend, Payable on October 1, 2024

Baxter: Why Investors Should Take Advantage Of The Low Valuation

Little Excitement Around Baxter International Inc.'s (NYSE:BAX) Revenues

Carlyle Group Reportedly in Advanced Talks to Buy Baxter's Vantive Business

Baxter International (NYSE:BAX) Has Affirmed Its Dividend Of $0.29

Baxter International Inc. Announces New Data Showing Expanded Hemodialysis, Known as HDX Therapy

Upcoming dividend of US$0.29 per share

Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29

Baxter International Inc. Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication

First quarter dividend of US$0.29 announced

Baxter International: Shares Too Cheap, EPS Growth Ahead With A Possible Spinoff

Baxter International Inc. Declares Quarterly Dividend, Payable on July 1, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Baxter International Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2024

Capital Allocation Trends At Baxter International (NYSE:BAX) Aren't Ideal

Baxter International Inc. Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S

Baxter International Inc. Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy

Baxter International Inc., Annual General Meeting, May 07, 2024

Broyhill - Baxter International: Renal Care Spin-Off And Recent Revamp Should Provide Catalysts

Upcoming dividend of US$0.29 per share

Baxter International's (NYSE:BAX) Dividend Will Be $0.29

Fourth quarter dividend of US$0.29 announced

Baxter International Inc. Declares Quarterly Dividend, Payable on April 1, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Baxter International Inc. Provides Sales Guidance for the First Quarter and Full Year 2024

Here's Why Baxter International (NYSE:BAX) Has A Meaningful Debt Burden

Baxter International (NYSE:BAX) Could Be Struggling To Allocate Capital

Baxter International Inc.'s (NYSE:BAX) Prospects Need A Boost To Lift Shares

Consensus EPS estimates increase by 109%

Baxter International Inc. Announces the Completion of the First Phase of Its Intravenous (IV) Bag Recycling Program Pilot

Baxter International: A Cheap Big Pharma Stock With Improving Earnings And +3% Dividend Yield

Price target decreased by 7.5% to US$45.07

Estimating The Fair Value Of Baxter International Inc. (NYSE:BAX)

Upcoming dividend of US$0.29 per share at 3.2% yield

Baxter International Inc. Declares Quarterly Dividend, Payable on January 2, 2024

Baxter International Inc. Highlights New Data At Kidney Week Indicating Sharesource Is Associated with A 77% Lower Risk of Home Dialysis Technique Failure

Baxter International Inc. Provides Earnings Guidance for the Fourth Quarter and Year 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations

Is Baxter International (NYSE:BAX) A Risky Investment?

Baxter International Inc. Digital Image Capture Capability for PanOptic Plus Ophthalmoscope

Should You Buy Baxter Or DaVita After The Fallout From The Ozempic Trial?

Baxter International Inc. Announces Management Appointments

There Are Reasons To Feel Uneasy About Baxter International's (NYSE:BAX) Returns On Capital

Levi & Korsinsky Notifies Baxter International Inc. Investors of A Class Action Lawsuit and Upcoming Deadline

Upcoming dividend of US$0.29 per share at 2.8% yield

Baxter International (NYSE:BAX) Is Due To Pay A Dividend Of $0.29

Baxter International Inc. Announces Board Changes

Dividend Challengers Review: Baxter International

The Klein Law Firm Announces That A Class Action Complaint Has Been Filed on Behalf of Shareholders of Baxter International Inc. Alleging That the Company Violated Federal Securities Laws

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Baxter International (NYSE:BAX) Has Announced A Dividend Of $0.29

Baxter International Inc. Launches PERCLOT Absorbable Hemostatic Powder

Now 20% undervalued

Baxter International Inc. Declares Quarterly Cash Dividend, Payable on October 2, 2023

Rosen Law Firm Announces the Filing of Class Action Lawsuit on Behalf of Purchasers of Securities of Baxter International Inc

Baxter International (NYSE:BAX) Has A Somewhat Strained Balance Sheet

High number of new directors

Baxter International Inc. Appoints William Ampofo to Its Board of Directors